Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cangfu Daotan Tang is a classic Traditional Chinese Medicine (TCM) formula primarily used to treat gynecological disorders associated with phlegm-dampness syndrome, most notably Polycystic Ovary Syndrome (PCOS) and related infertility. It is frequently studied in obese patients with PCOS to improve insulin resistance, hormonal balance, and endometrial receptivity. The formula typically consists of several herbs, including Rhizoma Cyperi (Xiangfu) and Rhizoma Atractylodis (Cangzhu), which give it its name. Research suggests it acts through multiple pathways, including the regulation of immune microenvironments via JUN and AKT targets, the NEK7-NLRP3 inflammatory pathway, and the HSP70/NF-κB/Caspase3 signaling cascade. It is often used as an adjuvant to assisted reproductive technologies like in vitro fertilization (IVF).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cangfu daotan tang.